Skip to main content

Zyomyx Adds Notch to Patent Belt

NEW YORK, April 2 - Proteomics company Zyomyx said today that it has been granted a second patent by the US Patent and Trademark Office for its protein-chip technology.

 

The patent, which was granted today, covers surface chemistry configurations and describes a variety of antibody arrays.

 

In January, the company secured a related patent on protein-chip surface and attachment technology.

 

Based in Hayward, Calif., Zyomyx is developing high density protein biochips based on a surface chemistry derived from high resolution microscopy. The company, which is privately owned, hopes to develop chips for up to 10,000 different proteins.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.